Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Unsupported price hikes added $815 mln to US drug spending in 2023
Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an influential drug pricing watchdog said on Thursday.
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
ICER Identifies 5 Drugs with Unsupported Price Increases
The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence,
Evidence Lacking for $815 Million Increase in 2023 Drug Spending
A review found half of the drugs studied had price increases based on new evidence of benefits, while the other half did not.
NHS spending on new drugs not best use of money, says study
Funding for expensive new drugs in England over the last two decades would have been better spent elsewhere in the NHS, according to a new study. The report published in The Lancet on Thursday evening found that the rollout of such drugs had come at a “heavy cost to the health of many others” as the cost was diverting resources from other kinds of healthcare that would have helped more patients.
Unsupported price hikes added $815 million to US drug spending in 2023
Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an influential drug pricing watchdog said on Thursday.
Seeking Alpha
1d
Genmab A/S: Circling Back On This Complicated Story
Although it was receiving revenue from eight products, royalties from Johnson & Johnson (JNJ) subsidiary Janssen’s ...
6d
ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
FiercePharma
2d
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
4d
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...
Cure Today
6d
Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...
FiercePharma
5d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
STAT
5d
Uniqure gets FDA OK to seek accelerated approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
6d
J&J : DARZALEX FASPRO Regimens Improve MRD Negativity, Survival In Newly Diagnosed Multiple Myeloma
Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...
7d
Genmab Is Too Attractive To Ignore
Genmab's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak. See why I rate ...
TipRanks on MSN
6d
J&J announces new frontline data featuring TECVAYLI fro 2 studies in NDMM
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
United States
GlaxoSmithKline
Johnson & Johnson
Blenrep
Cepheus
Feedback